Candel Therapeutics' CAN-2409 delivers durable benefit in positive phase 3 prostate cancer trial

By Proactive Investors / October 02, 2025 / www.youtube.com / Article Link


Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to highlight new subgroup analyses from the ...

Recent News

Gold and silver price ETFs see major net outflows
November 04, 2025 / canadianminingreport.com

Gold stocks decline by less than metal price
November 04, 2025 / www.canadianminingreport.com

A shift to the later stages of gold and silver bull markets
October 27, 2025 / www.canadianminingreport.com

Gold stocks plunge on metal drop
October 27, 2025 / www.canadianminingreport.com

Gold stocks still up after pullback late in the week
October 20, 2025 / www.canadianminingreport.com
See all >
Share to Youtube Share to Facebook Facebook Share to Linkedin Share to Twitter Twitter Share to Tiktok